Cell Source, Inc. (CLCS) Form 10-Q — May 14, 2026
Cell Source, Inc. reported a net loss of $1.48 million for the first quarter of 2025, driven by $515,000 in R&D expenses and $483,000 in general and administrative costs, with no revenue generated. The company ended the quarter with only $1,240 in cash and a working capital deficiency of $20.1 million, citing substantial doubt about its ability to continue as a going concern. Approximately $17.4 million in notes payable and convertible notes were past due as of March 31, 2025, including a notice of default on a $202,500 note.
Key figures
- Total Debt
- 11116000
- Cash Position
- 1240
- Shares Outstanding
- 67945856
- Ga Expense Q1
- 483404
- Rd Expense Q1
- 515183
- Past Due Notes Payable
- 6328000
- Subsequent Proceeds Debt
- 2839000
- Past Due Convertible Notes
- 11116000
Price after filing
Close on the filing date to close N calendar days later (from $0.82). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.